These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 10189289)

  • 1. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma.
    Muto Y; Moriwaki H; Saito A
    N Engl J Med; 1999 Apr; 340(13):1046-7. PubMed ID: 10189289
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. Updated analysis of the long-term follow-up data.
    Takai K; Okuno M; Yasuda I; Matsushima-Nishiwaki R; Uematsu T; Tsurumi H; Shiratori Y; Muto Y; Moriwaki H
    Intervirology; 2005; 48(1):39-45. PubMed ID: 15785088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deletion of serum lectin-reactive alpha-fetoprotein by acyclic retinoid: a potent biomarker in the chemoprevention of second primary hepatoma.
    Moriwaki H; Yasuda I; Shiratori Y; Uematsu T; Okuno M; Muto Y
    Clin Cancer Res; 1997 May; 3(5):727-31. PubMed ID: 9815742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polyprenoic acid in hepatocellular carcinoma.
    Decensi A; Costa A
    N Engl J Med; 1996 Nov; 335(19):1461; author reply 1461-2. PubMed ID: 8927082
    [No Abstract]   [Full Text] [Related]  

  • 5. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group.
    Muto Y; Moriwaki H; Ninomiya M; Adachi S; Saito A; Takasaki KT; Tanaka T; Tsurumi K; Okuno M; Tomita E; Nakamura T; Kojima T
    N Engl J Med; 1996 Jun; 334(24):1561-7. PubMed ID: 8628336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polyprenoic acid in hepatocellular carcinoma.
    Yang CH; Cheng AL
    N Engl J Med; 1996 Nov; 335(19):1460-61; author reply 1461-2. PubMed ID: 8927081
    [No Abstract]   [Full Text] [Related]  

  • 7. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma.
    Muto Y; Moriwaki H; Shiratori Y
    Digestion; 1998 Jul; 59 Suppl 2():89-91. PubMed ID: 9718434
    [No Abstract]   [Full Text] [Related]  

  • 8. Role of acyclic retinoid in the chemoprevention of hepatocellular carcinoma: basic aspects, clinical applications, and future prospects.
    Shimizu M; Imai K; Takai K; Moriwaki H
    Curr Cancer Drug Targets; 2012 Nov; 12(9):1119-28. PubMed ID: 22873214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthetic retinoids for the secondary prevention of hepatocellular carcinoma.
    Shafritz DA
    N Engl J Med; 1996 Jun; 334(24):1600-1. PubMed ID: 8628344
    [No Abstract]   [Full Text] [Related]  

  • 10. Need of stratifying patients according to severity of underlying liver disease for hepatocellular carcinoma patients undergoing systemic therapy trials.
    Yeo W; Mo FK; Hui P; Chan SL
    Contemp Clin Trials; 2010 Mar; 31(2):135. PubMed ID: 20123038
    [No Abstract]   [Full Text] [Related]  

  • 11. Sorafenib in hepatocellular carcinoma: separating the hype from the hope.
    Kelley RK; Venook AP
    J Clin Oncol; 2008 Dec; 26(36):5845-8. PubMed ID: 19029408
    [No Abstract]   [Full Text] [Related]  

  • 12. Malignant hepatoma.
    van Dyk JJ
    Proc Mine Med Off Assoc SA; 1975; 55(421):19-20. PubMed ID: 209446
    [No Abstract]   [Full Text] [Related]  

  • 13. Synergistic induction of apoptosis by acyclic retinoid and interferon-beta in human hepatocellular carcinoma cells.
    Obora A; Shiratori Y; Okuno M; Adachi S; Takano Y; Matsushima-Nishiwaki R; Yasuda I; Yamada Y; Akita K; Sano T; Shimada J; Kojima S; Okano Y; Friedman SL; Moriwaki H
    Hepatology; 2002 Nov; 36(5):1115-24. PubMed ID: 12395321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Liver resection. I].
    Oldhafer KJ; Stavrou GA
    Zentralbl Chir; 2006 Oct; 131(5):W54-66; quiz W67-8. PubMed ID: 17089283
    [No Abstract]   [Full Text] [Related]  

  • 15. Tamoxifen does not improve overall survival in people with advanced-stage hepatocellular carcinoma.
    Chow PK
    Cancer Treat Rev; 2005 Oct; 31(6):491-5. PubMed ID: 16214294
    [No Abstract]   [Full Text] [Related]  

  • 16. Nutritional pharmacotherapy of chronic liver disease: from support of liver failure to prevention of liver cancer.
    Moriwaki H; Tajika M; Miwa Y; Kato M; Yasuda I; Shiratori Y; Okuno M; Kato T; Ohnishi H; Muto Y
    J Gastroenterol; 2000; 35 Suppl 12():13-7. PubMed ID: 10779208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of FGF signaling: a putative mechanism for the chemopreventive effects of acyclic retinoid in hepatocellular carcinoma.
    Wang L; Levin MS
    Gastroenterology; 2005 Jan; 128(1):228-31. PubMed ID: 15633140
    [No Abstract]   [Full Text] [Related]  

  • 18. [Chemoprevention of hepatocellular carcinoma by acyclic retinoid].
    Nagaki M; Shimizu M; Moriwaki H
    Nihon Shokakibyo Gakkai Zasshi; 2008 Jun; 105(6):802-7. PubMed ID: 18525185
    [No Abstract]   [Full Text] [Related]  

  • 19. [Chemotherapy of hepatocellular carcinoma].
    Okada S
    Nihon Naika Gakkai Zasshi; 1995 Dec; 84(12):2028-31. PubMed ID: 8586926
    [No Abstract]   [Full Text] [Related]  

  • 20. Growth inhibition of human hepatoma cells by acyclic retinoid is associated with induction of p21(CIP1) and inhibition of expression of cyclin D1.
    Suzui M; Masuda M; Lim JT; Albanese C; Pestell RG; Weinstein IB
    Cancer Res; 2002 Jul; 62(14):3997-4006. PubMed ID: 12124333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.